• Home
Wanyi Tai

Picture

Contact Information:
Wanyi Tai, Ph.D.
Mailing address: N530B William H. Foege Building, 3720 15th Ave NE Seattle, WA, 98195-5061.
Phone: 206-543-0321
E-mail:wt8q9@umkc.edu

Education

09/2000—06/2004  
B.S., Pharmacy, China Pharmaceutical University
09/2004—06/2007 
M.S., Medicinal Chemistry, Shanghai Institute of Materia Medica, Chinese Academy of Sciences 
08/2007—08/2012 
Ph.D., Pharmaceutical Sciences, University of Missouri-Kansas City 
09/2012—11/2013
Postdoc., Biomedical Engineering, University of North Carolina at Chapel Hill and North Carolina State University 
12/2013—present
Senior postdoctoral fellow, University of Washington

Experimental skills

Organic synthesis, polymer synthesis, RNA isolation, real time PCR, molecular cloning, recombinant protein expressing and purification, western blotting, xenograft mode establishment (breast cancer and prostate cancer models), siRNA transfection, liposome preparation, NMR, HPLC, HPLC-MS/MS analysis, radioactive cellular uptake, IC50 profiling, ELISA, cancer cell culture, confocal microscopy.

Research experience

Post Doctoral Research:
-Develop a glucose oxidase mediated, glucose responsive polymersome nanovesicle for in vivo insulin delivery. : Joint Department of Biomedical Engineering, North Carolina State University and University of North Carolina at Chapel Hill, 2012-2013
-Fold graft copolymer into nanoparticles for in vivo cancer therapy through codelivery of camptothecin and doxorubicin.
Doctoral Research:
-Design and synthesis of peptide-drug conjugates for prostate cancer therapy. : Division of Pharmaceutical Sciences, University of Missouri-Kansas City, 2007-2012
-Evaluation of the expression profile and functional activity of peptide transporters in prostate cancer cells.
-Development of polymer rapamycin conjugates for cancer therapy.
-Analysis of the combinational treatment effect of HER2 and VEGF siRNAs on breast cancer cells.
-Identification of HER2 specific peptide by phage display.
Master’s Research:
-Synthesis of ring-open bengamide analogue library and analysis of its Structure Activity Relationship (SAR). : National Center for Drug Screening, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 2004-2007
-Facile synthesis of versatile functionalized amino caprolactams using RCM reactions.

Teaching experience

Teaching Assistant, Medicinal Chemistry II (PHARM 7344), University of Missouri-Kansas City

Award and honors

2010      Outstanding Leadership Award, University of Missouri-Kansas City
2003      The National Scholarship

Professional memberships

2009-2011             American Association of Pharmaceutical Scientists
2010-2011             Controlled Release Society
2010-Present       The Rho Chi Society

Publications

1.      Wanyi Tai, Zhijin Chen, Ashutosh Barve, Zhonghua Peng, Kun Cheng*. A novel rapamycin-polymer conjugate based on a new poly(ethylene glycol) multiblock copolymer. Pharmaceutical Research 2013 Sep. 26 (Epub ahead of print)

2.      Wanyi Tai, Zhijin Chen, Kun Cheng*. Expression profile and functional activity of peptide transporters in prostate cancer cells. Molecular Pharmaceutics 2013, 10(2): 477-487

3.      Bin Qin, Wanyi Tai, Ravi S Shukla, Kun Cheng*. Identification of a LNCaP-Specific Binding Peptide Using Phage Display. Pharmaceutical Research 2011, 28(10): 2422-2434

4.      Wanyi Tai, Ravi S. Shukla, Bin Qin, Benyi Li, Kun Cheng*. Development of a peptide-drug conjugate for prostate cancer therapy. Molecular Pharmaceutics 2011, 8(3):901-912 (Highlighted by SciBX, Global Medical Discovery and NewsRx etc)

5.      Rubi Mahato, Wanyi Tai, Kun Cheng*. Prodrug for improving tumor targetability and efficiency. Advanced Drug Delivery Review 2011, 63(8):659-670

6.      Wanyi Tai, Rubi Mahato, Kun Cheng*. The role of HER2 in cancer therapy and targeted drug delivery. Journal of Controlled Release 2010, 146(3):264-275

7.      Wanyi Tai, Bin Qin, Kun Cheng*. Inhibition of Breast Cancer Cell Growth and Invasiveness by Dual Silencing of HER-2 and VEGF. Molecular Pharmaceutics 2010, 7(2):543-556

8.      Wan-Yi Tai†, Run-Tao Zhang†, Yi-Ming Ma, Min Gu, Gang Liu, Jia Li, Fa-Jun Nan*. Design, Synthesis, and Biological Evaluation of Ring‐Opened Bengamide Analogues. ChemMedChem 2011, 6(9): 1555-1558. († These authors contributed equally).

9.      Gang Liu†, Yi-Ming Ma†, Wan-Yi Tai †, Chuan-Ming Xie, Yu-Lin Li, Jia Li and Fa-Jun  Nan*. (2008). Design, Synthesis, and Biological Evaluation of Caprolactam-Modified Bengamide Analogues. ChemMedChem 2008, 3, 74–78. († These authors contributed equally).

10.  Gang Liu, Wan-Yi Tai, Yu-Lin Li and Fa-Jun Nan*. (2006) Facile synthesis of versatile       functionalized amino caprolactams using RCM reactions of α-amino acrylamide . Tetrahedron Letters, 2006, 47, 3295-3298

Book Chapter
1.      Wanyi Tai, Kun Cheng*. (2013) “Advanced drug delivery in cancer therapy” In Mitra AK, Lee C. Cheng K. edits “Advanced drug delivery” Wiley-Blackwell, John Wiley & Sons, Inc.

Patent

Fa-Jun Nan, Jia Li, Jian Ding, Gang Liu, Chuan-Ming Xie, Yi Chen, Wan-Yi Tai,  Alpha-amino-N-substituted amides, pharmaceutical composition containing them and uses thereof.  International application No. PCT/CN2008/001996

Conference abstract

1. Wanyi Tai, Bin Qin, Kun Cheng. (2009) Inhibition of breast cancer cell growth via inhibiting HER-2 and VEGF using siRNA. AAPS National Biotechnology Conference. Abst. No. 000682. 
2. Wanyi Tai, Kun Cheng. (2010) Development of a Cell Specific Peptide-Drug Conjugate for Prostate Cancer Therapy. The 37th Annual Meeting & Exposition of the Controlled Release Society.
3. Bin Qin, Wanyi Tai, Kun Cheng. (2011) Synthesis of a peptide-siRNA conjugate for targeted delivery to breast cancer cells. 2011 AAPS Annual Meeting and Exposition.
Powered by Create your own unique website with customizable templates.